Covance discusses the US market access landscape for biosimilarsBy: SMi Group John will present a session that reviews key CMS policy developments for biosimilars and understanding the potential impact on commercial payers' policies. He will highlight coding and Medicare payment for currently available products, with an aim to give insight on the link betwing coding/payment and pricing, as well as discuss what this means for biosimilars approved in the future. The presentation will also assess implications for reimbursement hubs, patient assistance programs and other customer support resources. He joins a speaker line-up comprised of experts shaping up the biosimilars landscape in North America including representatives from Sandoz, Harvest Moon Pharmaceuticals, Momenta, Pfenex, FUJIFILM Diosynth, Oncobiologics, Adelio, Covance, Zuckerman & Spaeder and more. The full roster of speakers and their topics can be found on www.biosimilars- SMi's Biosimilars North America conference will explore significant developmental topics within the sector including the impact of FDA's newly implemented biosimilar interchangeability guidelines, the US market access landscape, and biosimilars of orphan drugs. Registration is now live on the event website and there For more information visit: www.biosimilars- 4th Biosimilars North America November 15 & 16, 2017 Renaissance Woodbridge Hotel, Iselin, NJ, USA www.biosimilars- --- END --- For delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- Photo: https://www.prlog.org/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|